75 related articles for article (PubMed ID: 38473991)
1. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
[TBL] [Abstract][Full Text] [Related]
2. Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs.
Feist PE; Sidoli S; Liu X; Schroll MM; Rahmy S; Fujiwara R; Garcia BA; Hummon AB
Anal Chem; 2017 Mar; 89(5):2773-2781. PubMed ID: 28194967
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Kazansky Y; Mueller HS; Cameron D; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Mundi PS; Kuwahara Y; Somwar R; Qu R; Califano A; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
bioRxiv; 2024 May; ():. PubMed ID: 38766189
[TBL] [Abstract][Full Text] [Related]
4. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
5. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
[TBL] [Abstract][Full Text] [Related]
6. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
8. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
9. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.
Bekric D; Neureiter D; Ablinger C; Dobias H; Beyreis M; Ritter M; Jakab M; Bischof J; Koller U; Kiesslich T; Mayr C
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900361
[TBL] [Abstract][Full Text] [Related]
12. Current understanding of epigenetics role in melanoma treatment and resistance.
Karami Fath M; Azargoonjahromi A; Soofi A; Almasi F; Hosseinzadeh S; Khalili S; Sheikhi K; Ferdousmakan S; Owrangi S; Fahimi M; Zalpoor H; Nabi Afjadi M; Payandeh Z; Pourzardosht N
Cancer Cell Int; 2022 Oct; 22(1):313. PubMed ID: 36224606
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics Regulates Antitumor Immunity in Melanoma.
Chen Y; Yi X; Sun N; Guo W; Li C
Front Immunol; 2022; 13():868786. PubMed ID: 35693795
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
Duarte D; Vale N
Curr Res Pharmacol Drug Discov; 2022; 3():100110. PubMed ID: 35620200
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
